Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

The Dow Jones Industrial Average (DJIA) tumbled 700 points at its lowest on Tuesday as investor sentiment hits the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

U.S. stock futures fall as President Donald Trump doesn't rule out a recession, and Oracle is set to report fiscal third-quarter results after the closing bell. Here's what investors need to know ...

Finance), implies that the stock could skyrocket by about 462% from its current levels. Does that make it a buy? Terns Pharmaceuticals focuses on developing weight loss and oncology medicines.

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...